BONE THERAPEUTICS: JTA-004’s top-line results in Q3 will be 2021 key catalyst for Bone Therapeutics | CORPORATE | EUR5.5(+112%)
BONE THERAPEUTICS - CORPORATE | EUR5.5(+112%)JTA-004’s top-line results in Q3 will be 2021 key catalyst for Bone Therapeutics
FY2020 results highlight a cash runway into November 2021
JTA-004’s pivotal phase III results are expected in Q3
ALLOB’s clinical study has been slightly impacted by COVID
Expansion of the MSC platform still planned
Bone Therapeutics is a biotechnology company with an advanced clinical pipeline of cell products for orthopaedic conditions and bone diseases (two Phase II/III and three Phase I/II clinical studies). These areas are characterized by high unmet medical needs due to the lack of efficacious and safe, non-invasive, treatments. Co. has two products in clinical trials, its allogeneic bone cell therapy product, ALLOB®, and its autologous bone cell therapy product, PREOB®. Co. is also conducting preclinical research on next generation products, such as combined cell-matrix products for large bone defects and maxillofacial.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.